Atea Pharmaceuticals (AVIR) | Stock Overview & Key Data

Atea Pharmaceuticals Inc. | Healthcare

$3.22

3.87%

| Atea Pharmaceuticals Stock Comparison:

Atea Pharmaceuticals vs Vertex Atea Pharmaceuticals vs Regeneron Atea Pharmaceuticals vs Cg Oncology Atea Pharmaceuticals vs Denali Therapeutics Atea Pharmaceuticals vs Ligand Atea Pharmaceuticals vs S&P 500 | Market

Chart Range Statistics Financials Returns Ownership Calculator FAQ

Atea Pharmaceuticals Performance Comparison

Loading chart data...

Atea Pharmaceuticals

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $3.09 High: $3.29

on June 3, 2025

52 Week Range

Low: $2.45 High: $4.14

on May 15, 2025

on September 17, 2024

All-Time High: $94.17 on February 8, 2021

Key Statistics

Market Cap i $252.5M

EPS i -1.64

P/E Ratio (TTM) i N/A

Forward P/E i -1.92

P/B Ratio i 0.61

PEG Ratio i -1.92

Div. Yield i 0.00%

ROE i -30.47%

Beta i 0.173

Debt to Equity i 0.35

Financial Highlights

Profitability

Gross Margin i N/A

Operating Margin i 0.00%

Profit Margin i 0.00%

Returns and Earnings

Return on Assets (TTM) i -12.77%

Return on Equity (TTM) i -30.47%

EBITDA i $-101.0M

Net Income (TTM) i $-139.5M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i N/A

Quarterly Earnings Growth i N/A

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Atea Pharmaceuticals AVIR	252.46M Small-cap	9.15%	8.78%	11.03%	-7.47%	-5.85%	-13.24%	-58.42%	-89.42%
Vertex VRTX	114.81B Large-cap	0.11%	-10.74%	-7.62%	-2.30%	10.04%	-7.56%	75.18%	66.26%
Regeneron REGN	65.36B Large-cap	-19.13%	-19.17%	-28.77%	-34.91%	-31.79%	-51.37%	-14.70%	-17.11%
Cg Oncology CGON	2.00B Small-cap	4.98%	-4.93%	6.73%	-23.24%	-7.53%	-23.24%	-23.52%	-23.52%
Denali Therapeutics DNLI	1.97B Small-cap	5.45%	-12.88%	-8.36%	-41.69%	-33.16%	-32.88%	-38.26%	-43.59%
Ligand LGND	1.95B Small-cap	0.70%	-3.76%	-8.76%	-14.66%	-5.60%	25.59%	106.59%	50.04%

Ownership & Short Interest

Insider Ownership i 11.58%

Institutional Ownership i 68.44%

Shares Short i 3M

Short Ratio i 7.06

Short % of Shares Outstanding i 4.47%

Average 10-Day Volume i 376K

Average 90-Day Volume i 475K

Atea Pharmaceuticals Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Atea Pharmaceuticals would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is AVIR's 52-week high and low?

In the last 52 weeks, Atea Pharmaceuticals reached a high of $4.14 (on September 17, 2024) and a low of $2.45 (on May 15, 2025).

What is the market cap and P/E ratio for AVIR?

Curious about Atea Pharmaceuticals's size and valuation? Its market capitalization stands at 252.46M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -1.92.

Does AVIR pay dividends? If so, what's the yield?

As for dividends, Atea Pharmaceuticals isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are Atea Pharmaceuticals's main competitors or similar companies to consider before investing?

When looking at Atea Pharmaceuticals, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	114.81B	Healthcare	Biotechnology	-7.56%	75.18%
Regeneron REGN	65.36B	Healthcare	Biotechnology	-51.37%	-14.70%
Cg Oncology CGON	2.00B	Healthcare	Biotechnology	-23.24%	-23.52%
Denali Therapeutics DNLI	1.97B	Healthcare	Biotechnology	-32.88%	-38.26%
Ligand LGND	1.95B	Healthcare	Biotechnology	25.59%	106.59%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Atea Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Atea Pharmaceuticals's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -30.47%, the Debt to Equity ratio from the most recent quarter is 0.35, and its Gross Profit Margin stands at N/A.

What is the recent revenue and earnings growth for AVIR?

Looking at Atea Pharmaceuticals's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.

How much of AVIR stock is held by insiders and institutions?

Wondering who owns Atea Pharmaceuticals stock? Company insiders (like executives and directors) hold about 11.58% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 68.44%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.